Add time:07/16/2019         Source:sciencedirect.com

BackgroundChemokine signaling through CCR3 is a key regulatory pathway for eosinophil recruitment into tissues associated with allergic inflammation and asthma. To date, none of the CCR3 antagonists have shown efficacy in clinical trials. One reason might be their unbiased mode of inhibition that prevents receptor internalization, leading to drug tolerance.

We also recommend Trading Suppliers and Manufacturers of CCR3 Antagonist (cas 275812-32-3). Pls Click Website Link as below: cas 275812-32-3 suppliers